Recalcitrant Issues and New Frontiers in Nano-Pharmacology.
Clicks: 265
ID: 77273
2019
Packaging of old pharma drugs into new packaging "nanoparticles" is called nano-pharmacology and the products are called nano-based drugs. The inception of nano-pharmacology research and development (R&D) is marked by the approval of the first nano-based drug Doxil in 1995 by the Food and Drug Administration. However, even after more than two decades, today, there are only ∼20 nano-based drugs in the market to treat cancers and brain diseases. In this article we share the perspectives of nanotechnology scientists, engineers, and clinicians on the roadblocks in nano-pharmacology R&D. Also, we share our opinion on new frontiers in the field of nano-pharmacology R&D that may allow rapid and efficient transfer of nano-pharma technologies from R&D to market.
| Reference Key |
bhardwaj2019recalcitrantfrontiers
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Bhardwaj, Vinay;Kaushik, Ajeet;Khatib, Ziad M;Nair, Madhavan;McGoron, Anthony J; |
| Journal | Frontiers in pharmacology |
| Year | 2019 |
| DOI | 10.3389/fphar.2019.01369 |
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.